C E Clavel

Summary

Country: France

Publications

  1. ncbi Human papillomavirus genotype distribution in tonsil cancers
    Jean Lacau St Guily
    Service d Oto Rhino Laryngologie et Chirurgie Cervico Faciale, Hopital Tenon, Université Paris 6 et Faculté de Médecine Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Paris, France
    Head Neck Oncol 3:6. 2011
  2. ncbi Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions
    C Clavel
    Cell Biology Unit, Laboratoire Pol Bouin, Reims, France
    Diagn Mol Pathol 9:145-50. 2000
  3. ncbi Expression of the E-cadherin-catenin complex in lung neuroendocrine tumours
    C E Clavel
    INSERM Unit U 514, I F R 53 and Laboratoire Pol Bouin, 45 rue Cognacq Jay, Hospital Maison Blanche, 51092 Reims, France
    J Pathol 194:20-6. 2001
  4. ncbi [Value of cervical screening by HPV DNA testing. It is legitimate to type HPV for the primary screening of cervix neoplasms]
    C Clavel
    Laboratoire Pol Bouin, CHU de Reims, 45, rue Cognacq-Jay, 51100 Reims, France
    Gynecol Obstet Fertil 30:896-8. 2002
  5. ncbi Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions
    C Clavel
    Laboratoire Pol Bouin, Hopital Maison Blanche, CHU de Reims, 45 rue Cognacq Jay, Reims 51100, France
    Br J Cancer 90:1803-8. 2004
  6. ncbi Usefulness of HPV testing in the follow-up of untreated cervical low grade lesions
    C Clavel
    Laboratory Pol Bouin, CHU de Reims, France
    Histol Histopathol 20:1085-91. 2005

Collaborators

  • O Graesslin
  • René Gabriel
  • Marianne Lorenzato
  • Jean Lacau St Guily
  • Francois Denis
  • Gérard Agius
  • Philippe Birembaut
  • Yann Leocmach
  • Christiane Mougin
  • Jean Luc Pretet
  • Anne Carole Jacquard
  • Agnès Beby-Defaux
  • Claire Okaïs
  • Benoit Soubeyrand
  • Didier Riethmuller

Detail Information

Publications6

  1. ncbi Human papillomavirus genotype distribution in tonsil cancers
    Jean Lacau St Guily
    Service d Oto Rhino Laryngologie et Chirurgie Cervico Faciale, Hopital Tenon, Université Paris 6 et Faculté de Médecine Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Paris, France
    Head Neck Oncol 3:6. 2011
    ..French data on HPV prevalence in tonsil cancers are scarce. The objective of this study was thus to assess the overall and type specific HPV prevalence in tonsil histological samples...
  2. ncbi Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions
    C Clavel
    Cell Biology Unit, Laboratoire Pol Bouin, Reims, France
    Diagn Mol Pathol 9:145-50. 2000
    ..Thus, persistent high-risk HPV infection detected with HC-II represents a reliable tool to select populations at risk for the development of high-grade cervical lesions...
  3. ncbi Expression of the E-cadherin-catenin complex in lung neuroendocrine tumours
    C E Clavel
    INSERM Unit U 514, I F R 53 and Laboratoire Pol Bouin, 45 rue Cognacq Jay, Hospital Maison Blanche, 51092 Reims, France
    J Pathol 194:20-6. 2001
    ..However, this study failed to detect any mutation in exon 3 of the beta-catenin gene, in the APC gene or in the E-cadherin gene. These data suggest another mechanism of regulation of beta-catenin in these tumours...
  4. ncbi [Value of cervical screening by HPV DNA testing. It is legitimate to type HPV for the primary screening of cervix neoplasms]
    C Clavel
    Laboratoire Pol Bouin, CHU de Reims, 45, rue Cognacq-Jay, 51100 Reims, France
    Gynecol Obstet Fertil 30:896-8. 2002
  5. ncbi Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions
    C Clavel
    Laboratoire Pol Bouin, Hopital Maison Blanche, CHU de Reims, 45 rue Cognacq Jay, Reims 51100, France
    Br J Cancer 90:1803-8. 2004
    ..We conclude that all these women could be safely screened at longer intervals between 3 and 5 years. This policy will offset the increased costs induced by an additional HR-HPV testing in primary screening...
  6. ncbi Usefulness of HPV testing in the follow-up of untreated cervical low grade lesions
    C Clavel
    Laboratory Pol Bouin, CHU de Reims, France
    Histol Histopathol 20:1085-91. 2005
    ..Thus HR-HPV testing should be reserved for the follow-up of this population of women initially HR-HPV+ and proposed 6 to 12 months after the cytological diagnosis of LSIL...